Printer Friendly

Dade Behring Launches Homocysteine on Its BN(TM) Systems; Addition Provides Physicians with one of the Most Complete Cardiovascular Menus in the Industry.

DEERFIELD, Ill. -- Dade Behring Inc. (NASDAQ:DADE), the world's largest company solely dedicated to clinical diagnostics and a pioneer in cardiac diagnostic testing, today announced that it has launched the homocysteine assay in the European marketplace(1) for use on its BN(TM) II and BN ProSpec(R) systems. Homocysteine is a cardiac marker used to determine if a person is at high risk of a heart attack or stroke. Up to 47% of patients with symptoms of cardiovascular disease show elevated levels of homocysteine. Dade Behring now provides physicians with one of the most complete cardiovascular risk assessment menus, allowing them to better diagnose a patient at risk of a heart attack.

"Because heart attacks are the leading cause of death in both men and women, providing physicians with a better way to assess the health of their at-risk patients is a major priority for us," said Jim Reid-Anderson, Chairman, President and CEO, Dade Behring. "The launch of this cardiac test reflects our commitment to helping clinicians find the best way to manage and assess cardiovascular disease in their patients and thus significantly improve patient outcomes."

Homocysteine is an amino acid which, when increased, is found to be associated with the progression of vascular disease(2,3). There are multiple factors that influence levels of homocysteine, including genetics, vitamins, lifestyle, chronic diseases, and drugs.

The homocysteine test may be run in a panel in conjunction with Dade Behring's CardioPhase(R) hsCRP, cholesterol, lipids, Apo A1/Apo B, Lp(a), and microalbuminuria tests. This cardiovascular risk assessment panel is run in both the routine and specialized laboratory.

Dade Behring co-developed the homocysteine test kit through an agreement with Axis-Shield plc. Axis-Shield is a global manufacturer of in vitro diagnostic kits in cardiovascular, rheumatoid, infectious and alcohol-related diseases, together with diabetes, and it has a special focus in near patient testing ( Dade Behring will sell and distribute this product under the Dade Behring name.

Dade Behring offers a full line of tests to help diagnose acute myocardial infarction and pulmonary embolism, and also screen for risk of heart disease. Dade Behring was the first to offer the Acute Care(TM) high-sensitivity Troponin I (defined as less than 10% coefficient variant at the 99th percentile of a normal reference population) and an automated high-sensitivity CRP to clinical laboratories. In addition, Dade Behring's CardioPhase(R) hsCRP was the first hsCRP assay to have a cardiac-specific claim as an independent marker for risk assessment and risk stratification.

About Dade Behring

With 2004 revenues of nearly $1.6 billion, Dade Behring is the world's largest company dedicated solely to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of labs, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the internet at

1. The homocysteine assay is not yet available in the U.S. Please contact your local representative regarding product availability in your country.

2. Journal of the Royal Society of Medicine 2001; 94: 10-13

2. British Journal of Medicine 2002; 325; 1202-1206
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 27, 2005
Previous Article:Xelor Quality Survey Reveals Dissatisfaction Among Adopters and Evaluators of Enterprise IP Telephony.
Next Article:Lucille Levesque Wins Biotechnology Teacher-Leader Award Using LABTrack at BIO 2005!

Related Articles
Study Finds That a Low-Cost Measure for C-Reactive Protein - CRP - Can Be a Highly Effective Tool To Identify Risk of Heart Disease.
Dade Behring Launches N Latex CDT for Use on Its BN Systems; First Direct Immunoassay to Identify Chronic Alcohol Abuse.
Competitive Technologies Licenses Homocysteine Assay to Dade Behring.
Dade Behring Grants Sublicense to Abbott for the Use of Placental Growth Factor (PlGF) for the Diagnosis of Cardiovascular Diseases.
Dade Behring Launches Viva-Jr(TM) Drug Testing System; New system provides criminal justice and low-volume clinical laboratories with the most...
Frost & Sullivan Recognizes Dade Behring for Excellence in Customer Service Leadership.
Dade Behring Grants Rights to American Diagnostica for the Use of Factor VII-Activating Protease (FSAP).
Dade Behring Launches CardioPhase(R) hsCRP Test for Use on Its Dimension(R) Systems; Addition extends use of a cardiac-specific hsCRP test to...
Dade Behring Launches CardioPhase(R) hsCRP Test for Use on Its Stratus(R) CS Acute Care(TM) Diagnostic System.
TRx Pharma Introduces FOLMOR for the Treatment of Cardiovascular Disease.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters